talquetamab
janssen
['monumental-1', 'talquetamab', 'mmsm']
congress #eha2023 | cyrille touzeau presents the results of monumental-1 a phase ii study of talquetamab for rrmm. n=339. in the pivotal cohorts, orr was 74.1% (qw, 18.8 mo mf/u) &amp; 71.7% (q2w, 12.7 mo mf/u), with vgpr in 59.4% (qw) &amp; 60.7% (q2w). #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma